{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:58:42Z","timestamp":1789750722049,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1038\/nrneurol.2014.216","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T10:26:42Z","timestamp":1415701602000},"page":"679-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Towards more-accurate diagnosis in neuromyelitis optica"],"prefix":"10.1038","volume":"10","author":[{"given":"Kazuo","family":"Fujihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"BFnrneurol2014216_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough, D. J. et al. Treatment of neuromyelitis optica: review and recommendations. Mult. Scler. Relat. Disord. 1, 180\u2013187 (2012).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"BFnrneurol2014216_CR2","doi-asserted-by":"publisher","unstructured":"Pittock, S. J. et al. Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol. http:\/\/dx.doi.org\/10.1001\/jamaneurol.2014.1581 .","DOI":"10.1001\/jamaneurol.2014.1581"},{"issue":"Suppl. 63","key":"BFnrneurol2014216_CR3","doi-asserted-by":"crossref","first-page":"S63.001","DOI":"10.1212\/WNL.82.10_supplement.S63.001","volume":"82","author":"D Wingerchuk","year":"2014","unstructured":"Wingerchuk, D. et al. Revised diagnostic criteria of neuromyelitis optica spectrum disorders (S63.001). Neurology 82 (Suppl. 63), S63.001 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol2014216_CR4","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106\u20132112 (2004).","journal-title":"Lancet"},{"key":"BFnrneurol2014216_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473\u2013477 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2014216_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","volume":"3","author":"K Fujihara","year":"2012","unstructured":"Fujihara, K. et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin. Exp. Neuroimmunol. 3, 58\u201373 (2012).","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"BFnrneurol2014216_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1212\/WNL.0b013e31822c61b1","volume":"77","author":"S Siritho","year":"2011","unstructured":"Siritho, S., Nakashima, I., Takahashi, T., Fujihara, K. & Prayoonwiwat, N. AQP4 antibody-positive Thai cases, clinical features and diagnostic problems. Neurology 77, 827\u2013834 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2014216_CR8","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1212\/WNL.0b013e318296ea08","volume":"80","author":"DK Sato","year":"2013","unstructured":"Sato, D. K. et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 80, 2210\u20132216 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2014216_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"P Waters","year":"2012","unstructured":"Waters, P. et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78, 665\u2013671 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol2014216_CR10","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","volume":"80","author":"R Marignier","year":"2013","unstructured":"Marignier, R. et al. Aquaporin-4 antibody\u2013negative neuromyelitis optica: distinct assay sensitivity\u2013dependent entity. Neurology 80, 2194\u20132200 (2013).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.216","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:33:02Z","timestamp":1717540382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["BFnrneurol2014216"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2014.216","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]},"assertion":[{"value":"11 November 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.F. serves on scientific advisory boards for Alexion Pharmaceuticals, Bayer Schering Pharma, Biogen Idec, Chugai Pharmaceutical, Merck Serono, Mitsubishi Tanabe Pharma Corporation, Nihon Pharmaceutical, Novartis Pharma and Ono Pharmaceutical. He has received travel funding and speaker honoraria from Asahi Kasei Medical Co., Astellas Pharma Inc., Bayer Schering Pharma, Biogen Idec, Cosmic Corporation (a distributer of ELISA to detect aquaporin AQP4-IgG in Japan), Daiichi Sankyo, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma and Takeda Pharmaceutical Company, Ltd; and research funding from Asahi Kasei Medical Co., Bayer Schering Pharma, Biogen Idec Japan, Eisai Inc., Kowa Pharmaceuticals America, Inc., Mitsubishi Tanabe Pharma Corporation, Teva Pharmaceutical K.K., Teijin Pharma, and The Chemo-Sero-Therapeutic Research Institute. J.P. has received conference funding for scientific meetings and honoraria for advisory work from Bayer Schering, Biogen Idec, Chugai Pharma, Merck Serono, Novartis, Ono Pharmaceutical Co. Ltd and Teva. She has received unrestricted research grants from Bayer Schering, Biogen Idec, Merck Serono and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}